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Abstract
Background Preeclampsia is characterized by damage to
the maternal endothelium that has been suggested to be
mediated in part by elevated shedding of inXammatory pla-
cental syncytiotrophoblast micro-particles (STBM) into the
maternal circulation. Previously, we have shown that
STBM, prepared by three diVerent methods: mechanical
dissection, in vitro placental explants culture and perfusion
of placenta, can inhibit endothelial cell proliferation. Only
mechanically prepared STBM induced apoptosis in the
endothelial cells. Now, we have examined lipid levels in
the three STBM preparations and their diVerential
responses on endothelial cells.
Methods We examined the lipid levels in the three STBM
preparations using thin layer chromatography. Further-
more, the eVects of reduced lipid levels in the three STBM
preparations using the pharmacological agent methyl--
cyclodextrin were examined on endothelial cell prolifera-
tion and apoptosis.
Results Among the three STBM preparations, mechanical
STBM contained highest levels of lipids. The reduction in
lipid levels in mechanical STBM reduced their potential to
inhibit human umbilical vein endothelial cells (HUVEC)
proliferation and blocked their potential to induce apopto-
sis. No similar eVect was observed following lipid reduc-
tion in the two other STBM preparations.
Conclusions As it has been suggested that mechanically
derived STBM may more closely resemble placental micro-
particles generated in preeclampsia, our data suggest that
lipid content may play a role in the anti-endothelial defects
present in this disease.
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Abbreviations
PBS Phosphate buVered saline
STBM Syncytiotrophoblast micro-particles
MCD Methyl--cyclodextrin
HUVEC Human umbilical vein endothelial cells
Introduction
Preeclampsia is a severe obstetric disorder aVecting about
2–7% of pregnant women [1, 2]. Its features include high
blood pressure, proteinuria and edema [1]. This disorder is
associated with a considerable risk for feto-maternal mor-
bidity and mortality [3]. Recent research has indicated that
these diverse arrays of symptoms may be the result of an
excessive maternal systemic inXammatory response to
pregnancy, involving activation of the innate immune sys-
tem and damage of the maternal endothelial compartment
[3, 4].
It is well established that the placenta plays a central role
in the underlying etiology of preeclampsia and it has been
suggested that the elevated release of syncytiotrophoblast
derived micro-particles (STBM) may contribute to this
pathology, which aVects both the maternal endovasculature
and immune systems [2, 4, 5]. In normal pregnancy, tro-
phoblast cells and STBM are spontaneously released from
the placenta as a sign of normal placental physiologic turn-
over [6–8]. This phenomenon has been associated with the
mild inXammatory state accompanying pregnancy [3, 9].
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are shed in greater quantities by the placenta in preeclamp-
sia and that STBM generated in vitro by mechanical dissec-
tion of the placenta suppresses endothelial cell proliferation
[10]. This increased shedding of sub-cellular material paral-
lels the raise in circulating cell-free fetal DNA [11, 12],
demonstrating the increased placental dysfunction associ-
ated with the disorder [13]. Therefore, it has been proposed
that the increased shedding of STBM into the maternal
blood of women with preeclampsia could be responsible for
the manifest dysfunction of the vascular endothelium [9].
In order to study the eVect of STBM in greater detail,
recently we have characterized three diVerent STBM prepara-
tions [14]. The eVects of three STBM preparations were exam-
ined on endothelial cells and puriWed T cells [14, 15]. Among
the three STBM preparations, mechanically derived STBM
(mSTBM) preparation largely behaved in a diVerent manner
than the other two preparations, i.e. villous explants STBM
(vSTBM) and placental perfusion STBM (pSTBM) [14]. We
observed that only mSTBM signiWcantly inhibited endothelial
cell proliferation and induced apoptosis of these cells [14].
It has been proposed that preeclampsia and atherosclerosis
share similar symptoms [16–18]. In this regard lipids have
been shown to play an important role in the pathogenesis of
both diseases [16–18]. As STBM are the products of syncy-
tiotrophoblast cell layer of the villous tree, they should con-
tain membrane lipids, which might play a role in the
pathogenesis of preeclampsia. Therefore, in this study, we
examined lipids levels in diVerent STBM preparations. More-
over, lipid levels could be reduced from the STBM prepara-
tions and the eVects of these various STBM preparations were
examined on endothelial cell proliferation and apoptosis.
Materials and methods
Preparation of syncytiotrophoblast micro-particles
This study was approved by the Cantonal Institutional Review
Board of Basel, Switzerland. Written informed consent was
requested in all instances. Placentae and umbilical cords were
obtained after normal term delivery or elective cesarean sec-
tion from uncomplicated pregnancies and processed within
30–90 min of collection. STBM were prepared by three
diVerent methods as described previously [14]. The protein
content in each STBM preparation was quantiWed with the
advanced protein assay reagent (Cytoskeleton Inc. Denver,
CO, USA) according to the manufacturer’s instructions.
Lipid analysis of STBM
One hundred micrograms of the each STBM preparation
was extracted with chloroform. After centrifugation for
1 min the lipid containing lower organic layer was collected
and applied to the pre-coated thin layer chromatography
(TLC) plate. TLC was carried out in the pre-saturated
chamber. The running buVer consisted of chloroform:meth-
anol:water:ammonium hydroxide 65:30:3:2 (v/v/v/v). The
TLC run was monitored until the top of the plate. The sepa-
rated lipids were visualized by staining with mosatin stain
[4% ammonium molybdate tetrahydrate (w/v) + 0.08%
cesium sulfate tetrahydrate (w/v) + 30% H2SO4 (10%, v/v)]
and charring at 200°C.
Lipid reduction from STBM
One hundred micrograms of the each STBM preparation
was incubated with varying concentrations (2–8%) of
methyl--cyclodextrin (MCD) at RT for 30 min. After
incubation with MCD STBM were pelleted down and
resuspended in sterile phosphate buVered saline (PBS). Lip-
ids were extracted from MCD treated STBM and the
supernatants as described above. TLC was carried out to
conWrm the lipid reduction from the STBM preparations
and their appearance in the supernatants.
Cell proliferation assay
Human umbilical vein endothelial cells were isolated from
normal term human umbilical cord by the method described
by JaVe et al. [19, 20] and stored in liquid nitrogen until
use. Cells from passage 2 to 7 were used for all experi-
ments. HUVEC proliferation was measured using cell pro-
liferation kit (Roche Diagnostics, Basel, Switzerland),
which measures BrdU incorporation during DNA synthesis.
In brief, 1.5 £ 104 cells were plated onto 1% gelatin coated
96 well microtiter plates (Nunc, Denmark) in endothelial
serum-free medium (E-SFM) supplemented with 20 ng/ml
human recombinant basic Wbroblast growth factor (bFGF)
and 10 ng/ml human recombinant epidermal growth factor
(EGF) (GIBCO Invitrogen Life Technologies, Grand
Island, NY, USA). After 6 h, the culture medium was
replaced with untreated STBM or MCD treated STBM
diluted in DMEM:F12 medium supplemented with 1%
antimycotic/antibiotics, 10% FCS, 50 U/ml aprotinin, 25 U/
ml heparin (DMEM:F12 complete medium). The cells were
then incubated for 22 h, followed by an additional incuba-
tion with 10 M of BrdU for a further 18 h. The amount of
incorporated BrdU was detected using an ELISA reader
(Molecular Devices, Sunnyvale, CA, USA) according to
the manufacturer’s instructions.
Human umbilical vein endothelial cells apoptosis
Apoptosis was measured using a commercial cellular DNA
fragmentation ELISA kit (Roche Diagnostics, Germany).123
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ments into the cytoplasm during apoptosis. In brief, 2 £ 104
HUVEC were plated in 96 well microtiter plates (Nunc,
Denmark) in E-SFM culture medium supplemented with
20 ng/ml bFGF and 10 ng/ml EGF. After 6 h 10 M BrdU
was added and incubated for a further 18 h. Following
BrdU labeling, the cell monolayer was washed with sterile
PBS, then MCD treated and untreated STBM containing
DMEM:F12 complete medium was added for 24 h. In posi-
tive control wells, apoptosis was induced with 5 M stauro-
sporine (Sigma Chemicals, St Louis, MO, USA), a potent
inducer of apoptosis, for 3 h. The detection of BrdU labeled
apoptotic DNA fragments was performed according to the
manufacturer’s instructions.
Results
Mechanical STBM were rich in lipids
All three STBM preparations were applied to TLC plate
after the lipid extraction as described in “Materials and
methods”. Five spots were observed on the run front of the
TLC plate. Using commercially available cholesterol as a
standard, spot at the top of the TLC plate run was identiWed
as cholesterol. This analysis also revealed that the lipid
concentration in the mSTBM is greater than the other two
STBM preparations (Fig. 1). These data indicate the possi-
bility of mSTBM to be richer in membrane materials than
the other two STBM preparations at equal protein concen-
tration.
Methyl--cyclodextrin eYciently reduced lipids 
from STBM
It has been previously shown that membrane lipids can
eYciently be depleted using MCD [21]. Therefore, we
reduced lipids from all the three STBM preparations as
described in “Materials and methods”. In a dose-dependent
manner large amounts of lipids could be reduced from
mSTBM (Fig. 2a). Moreover, the reduced lipids appeared
in the supernatant of the treated mSTBM (Fig. 2a). On the
other hand, low levels of lipids present in pSTBM and
vSTBM could be depleted by the lowest concentration of
MCD (2%) (Fig. 2b). These observations suggest that
MCD could eVectively reduce membrane lipids in all
three STBM preparations.
Lipid reduction from mechanically derived STBM 
reduced their potential to inhibit HUVEC proliferation
It has been previously reported that the three STBM prepa-
rations can inhibit endothelial cell proliferation in a dose
dependant manner [14]. Therefore, we examined whether
the lipid depletion of the three diVerent STBM aVected
HUVEC proliferation. The eVects of equal amounts of nor-
mal and lipid depleted STBM, as determined by protein
content, were compared on HUVEC proliferation. For this
analysis we made use of highest concentration (12 g/well)
of each STBM preparation as this dose has previously been
shown to inhibit maximal HUVEC proliferation [14]. We
observed that upon lipid reduction the inhibition of
HUVEC proliferation by mSTBM (90% at 12 g untreated
Fig. 1 Thin layer chromatographic analysis of diVerent STBM prepa-
rations. Lipids were extracted from 100 g of the each STBM prepara-
tion as described in “Materials and methods” and applied to the pre-
coated TLC plate. TLC was carried out in the pre-saturated chamber.
The TLC run was monitored until the top of the plate. The separated
lipids were visualized after staining. This analysis revealed Wve lipid
spots in all STBM preparations. This analysis also conWrmed that the
mSTBM are rich in membrane lipids
Fig. 2 Lipid reduction in diVerent STBM preparations. One hundred
micrograms of the each STBM preparation was incubated with varying
doses of MCD for 30 min and then lipids were extracted as described
in “Materials and methods”. Lipids were also extracted from the super-
natants of MCD treated STBM. Treated and untreated STBM were
applied to the pre-coated TLC plate. TLC was carried out in the pre-
saturated chamber. This analysis revealed that lipids from mSTBM
could eYciently be reduced in the dose-dependant manner and deplet-
ed lipids could be observed in the supernatant (a). On the other hand,
lipids from pSTBM and vSTBM could be depleted totally with the low-
est concentration (2%) of MCD (b)123
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MCD treated mSTBM per well). On the other hand, lipid
depletion of the villous explants STBM and placental per-
fusion STBM, at similar dose, did not lead to a decrease in
the inhibition of endothelial cell proliferation (Fig. 3).
Lipid reduction from mechanically derived STBM 
abolished their potential to induce HUVEC apoptosis
We have previously reported that among the three STBM
preparations only mSTBM induced HUVEC apoptosis in a
dose-dependant manner [14]. Therefore, we examined
whether lipid depletion of mSTBM reduced their potential
to induce apoptosis in HUVEC. We observed that the apop-
tosis induced by mSTBM at highest concentration, 28%
apoptosis at 12 g untreated mSTBM per well, could be
abolished after lipid reduction in this STBM preparation
when used at similar dose (Fig. 4).
Discussion
In this study, we extend upon previous study in which three
diVerent STBM preparations were characterized morpho-
logically and functionally [14]. Now, we have examined
lipid levels in these STBM preparations using TLC. In this
regard it has been previously reported that high lipid con-
tent leads to endothelial cell dysfunction in many diseases
such as hypercholesterolemia, preeclampsia, inXammation
and hypertension [18, 22]. Our TLC analysis of the three
STBM preparations revealed mSTBM has the highest lipids
content, when compared to the other two STBM prepara-
tions. As STBM are derived from the syncytiotrophoblast
membrane layer of the placenta, it is most likely that the
lipids present in these STBM preparations are of membrane
origin. Large amounts of lipids present in mSTBM indicate
the high levels of membranous material present in this
preparation, which is in agreement with our previous obser-
vation where mSTBM contains large amounts of GPI,
anchored lipid membrane enzyme, placental like alkaline
phosphatase (PLAP) [14].
Three STBM preparations have been shown to reduce
HUVEC proliferation, among them mSTBM had the great-
est eVect and induced endothelial cell death by apoptosis
[14]. As this functional disparity of the STBM on endothe-
lial cell culture was not clear at that time, we examined
whether this eVect is due to the excess lipid content present
in mSTBM. For this purpose we reduced lipids from the
three STBM preparations using MCD. We observed that
lipid decrease in the STBM preparations resulted in the
reduced inhibition of HUVEC proliferation by mSTBM.
No similar eVects were noticed with the other two STBM
preparations. Moreover, lipid reduction in mSTBM blocked
their potential to induce apoptosis. Hence, these observa-
tions provide further evidence that the three STBM diVer in
their biochemical composition as well. As the extent of
HUVEC proliferation inhibition by lipid-depleted mSTBM
was similar to that mediated by pSTBM or vSTBM in their
native form, suggesting that lipids contribute partially to
the inhibition of HUVEC proliferation and subsequent
apoptosis. Therefore, these data suggest that excessive
HUVEC proliferation inhibition and apoptosis induction
mediated by the mSTBM in its native form may be due to
the high levels of lipids present in these particles.
Fig. 3 Reduction in the inhibition of endothelial cell proliferation by
mSTBM. Sub-conXuent HUVEC cells were incubated for 40 h with
each STBM preparation (untreated or MCD treated) in DMEM:F12
complete medium. Cell proliferation was measured as described in
“Materials and methods” and is represented as the percentage of cell
proliferation relative to untreated control as 100% cell proliferation.
This data suggested that the HUVEC proliferation inhibition could be
reduced only by lipid-depleted mSTBM not by the other two STBM
preparations. Analysis of STBM preparations from six placentae is
illustrated. Error bars represent standard deviation (§SD)
Fig. 4 Inhibition of endothelial cell apoptosis by mSTBM. ConXuent
HUVEC were incubated with 12 g/well concentration of untreated
and MCD treated mSTBM (mSTBM*) preparations and apoptosis was
measured as described in “Materials and method”. Five micromolar
staurosporine (STS) was used as positive control. Apoptosis is ex-
pressed as percentage relative to staurosporine-induced apoptosis,
which was designated as 100%. A single representative experiment is
shown out of three experiments123
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cental particles is a continuous feature of normal preg-
nancy, which increases during pregnancy due to an increase
in placental size. In this context, it has been proposed the
vSTBM and pSTBM prepared from explants cultures or
placental perfusion, respectively, may more closely mimic
micro-particles released by normal syncytiotrophoblast
turnover [23]. On the other hand mSTBM, which are gener-
ated by mechanical disruption of villous integrity, may be
more similar to particles released by the process of apo-
necrosis, which have been proposed to occur in the pre-
eclamptic placentae due to oxidative stress [23]. Therefore,
it will be interesting to examine in future whether STBM
from preeclamptic patients exhibit higher levels of lipids
akin to what we have observed in mSTBM.
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